FDA approves ENFLONSIA for RSV protection in newborns Single-dose protection lasts through the full RSV season ...

LONDON, UK I June 13, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

It starts with a sniffle. A mild cough. You tell yourself it’s just a cold—babies get those, right? But make no mistake. RSV ...

The shot is approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. Read more at straitstimes.com. Read more at straitstimes.com.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the ...

The number of Australians vaccinated against influenza is "worryingly low", health experts say, as new data reveal the winter ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

People in Northern Ireland are being reminded that a potentially life-saving vaccination aimed at protecting newborns and ...

A vaccine targeting a serious respiratory illness that hits infants hard has resulted in a 75 per cent reduction in babies hospitalised with the virus.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Here’s what causes colds to spread so easily, how long they are usually contagious and how they’re most commonly treated.